Advertisement

Testing for Human Retrovirus Infections: Medical Indications and Ethical Considerations

  • John W. Ward

Abstract

In 1985 the first tests became available to identify antibody to the retro-virus subsequently called the human immunodeficiency virus (HIV). Since that time HIV antibody testing has become the cornerstone of public health efforts to stop the epidemic of HIV infection. The tests were used initially to screen donated blood and plasma, and their use for this purpose dramatically decreased the rate of transfusion-associated (TA) HIV transmission.1’2 Soon thereafter, testing linked with counseling was recommended as a method to encourage safer sexual and drug use practices3’4 and to aid in the diagnosis of some conditions associated with HIV infection, including those in the acquired immunodeficiency syndrome (AIDS) surveillance case definition.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Human Immunodeficiency Virus Infection Human Immunodeficiency Virus Transmission Human Immunodeficiency Virus Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    CDC. Provisional Public I-Iealth Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. MMWR 1985;34:1–5Google Scholar
  2. 2.
    Ward J, Holmberg SD, Allen JR, et al. Human immunodeficiency virus (HIV) transmission by blood transfusions screened negative for HIV antibody. N Engl J Med 1988;318:473–478PubMedCrossRefGoogle Scholar
  3. 3.
    CDC. Additional recommendations to reduce sexual and drug abuse related transmission of human T-Iymphotropic virus type III/lymphadenopathyassociated virus. MMWR 1986;35:152–155Google Scholar
  4. 4.
    CDC. Public health service guidelines for counseling and antibody testing to prevent IIIV infection and AIDS. MMWR 1987;36:509–515Google Scholar
  5. 5.
    CDC, Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36:1–15SGoogle Scholar
  6. 6.
    DesJarlais DC, Friedman SR. The psychology of preventing AIDS among intravenous drug users: a social learning conceptualization. Am Psychol 1988;43:865–870CrossRefGoogle Scholar
  7. 7.
    Godfried JR, Van Griensven MS, Ernest MM, et al. Impact of HIV antibody testing on changes in sexual behavior among homosexual men in The Netherlands. Am J Public Health 1988;78:1575–1577CrossRefGoogle Scholar
  8. 8.
    McCusker J, Stoddard AM, Mayer KH, et al. Effect of HIV antibody test knowledge on subsequent sex behaviors in a cohort of homosexual men. Am J Public Health 1988:78462–78467Google Scholar
  9. 9.
    McCusker J, Stoddard AM, Zapka JG, Zorn M, Mayer KH. Predictors of AIDS preventive behavior among homosexually active men: a longitudinal study. AIDS 1989;3:443–338PubMedCrossRefGoogle Scholar
  10. 10.
    Higgins DL, Lavotti O’,Reilly KR, et al. Evidence for the effect of HIV antibody counseling and testing on risk behavior. JAMA 1991;266:2419–2429PubMedCrossRefGoogle Scholar
  11. 11.
    Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990;322:941–949PubMedCrossRefGoogle Scholar
  12. 12.
    Abowker J-P, Swart AM. Preliminary analysis of the Concorde trial. Lancet 1993;341:889–890CrossRefGoogle Scholar
  13. 13.
    Ragni MV, Kingsley LA, Zhou SJ. The effect of antiviral therapy on the natural history of human immunodeficiency virus infection in a cohort of hemophiliacs. J Acquir Immune Defic Syndr 1992;5:120–126PubMedGoogle Scholar
  14. 14.
    CDC. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus disease. MMWR 1992;41(RR-4)Google Scholar
  15. 15.
    CDC. General recommendations on immunization. MMWR 1989;38:207–227Google Scholar
  16. 16.
    CDC. Screening for tuberculosis and tuberculous infection in high-risk populations and the use of preventive therapy for tuberculous infection in the United States: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1990;39:RR-8Google Scholar
  17. 17.
    CDC. Estimates of HIV prevalence and projected AIDS cases: summary of a workshop, October 31—November 1, 1989. MMWR 1990;39:110–112Google Scholar
  18. 18.
    Henry K, Maki M, Crossley K. Analysis of the use of 111V antibody testing in a Minnesota hospital. JAMA 1986;259:229–232CrossRefGoogle Scholar
  19. 19.
    Sherer R. Physician use of the HIV antibody test: the need for consent, counseling, confidentiality, and caution. JAMA 1988;259:264–265PubMedCrossRefGoogle Scholar
  20. 20.
    Dickens BM. Legal rights and duties in the AIDS epidemic. Science 1988; 239:580PubMedCrossRefGoogle Scholar
  21. 21.
    Walters L. Ethical issues in the prevention and treatment of HIV infection and AIDS. Science 1988;239:597PubMedCrossRefGoogle Scholar
  22. 22.
    CDC. Update: serologic testing for antibody to human immunodeficiency virus. MMWR 1988;36:833–840, 845Google Scholar
  23. 23.
    Weiss SH, Goedart JJ, Sarngadharan MB, et al. Screening test for HTL-III (AIDS) agent antibodies; specificity, sensitivity, and applications. JAMA 1985;253:221–225PubMedCrossRefGoogle Scholar
  24. 24.
    Ward J, Grindon AJ, Feorino PM, et al. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. JAMA 1986;256:357–361PubMedCrossRefGoogle Scholar
  25. 25.
    Horsburg CR J, Ou CY, Jason J, et al. Duration of human immunodeficiency virus infection before detection of antibody. Lancet 1989;2:637–640CrossRefGoogle Scholar
  26. 26.
    Pan LZ, Sheppard HW, Winkelstein W, et al. Lack of detection of human immunodeficiency virus in persistently seronegative homosexual men with high or medium risks for infection. J Infect Dis 1991;164:962–964PubMedCrossRefGoogle Scholar
  27. 27.
    Ou CY. Kwok S, Mitchell SW, et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988;239: 295–297PubMedCrossRefGoogle Scholar
  28. 28.
    Saag MS, Britz J. Asymptomatic blood donor with a false positive HTLV-III Western blot. N Engl J Med 1986;314:118PubMedGoogle Scholar
  29. 29.
    CDC. Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections. MMWR 1989;38(suppl 7S)Google Scholar
  30. 30.
    Benenson AS, Peddercord M, Hofherr LK, et al. Reporting the results of human immunodeficiency virus testing. JAMA 1989;262:3435–3438PubMedCrossRefGoogle Scholar
  31. 31.
    Lo B, Steinbrook RL, Cooke M. et al. Voluntary screening for human immunodeficiency virus (HIV) infection. Ann Intern Med 1989;110:727–733PubMedGoogle Scholar
  32. 32.
    Gostin LO. The AIDS litigation project; a national review of court and human rights commission decision. Part 2. Discrimination. JAMA 1990;263: 2086–2093PubMedCrossRefGoogle Scholar
  33. 33.
    Landesman SH, DeHovitz JA. HIV diagnostic testing: ethical, legal, and clinical considerations. Sex Transm Dis 1990;81:975–983Google Scholar
  34. 34.
    Bayer R. Editorial review: ethical and social policy issues raised by HIV screening: the epidemic evolves and so do the challenges. AIDS 1989;3:119–124PubMedCrossRefGoogle Scholar
  35. 35.
    Levine C, Bayer R. The ethics of screening for early intervention in HIV disease. Am J Public Health 1989;79:1661–1667PubMedCrossRefGoogle Scholar
  36. 36.
    CDC. Recommendations for HIV testing services for inpatients and outpatients in acute-care hospital setting; and technical guidance on HIV counseling. MMWR 1993;42(no. RR-2)Google Scholar
  37. 37.
    CDC. 1989 Sexually transmitted diseases treatment guidelines. MMWR 1989; 38:S-8Google Scholar
  38. 38.
    CDC. Recommendations for counseling persons infected with human Tlymphotrophic virus, types I and II: recommendations on prophylaxis and therapy for disseminated Myrobaterium avium complex; four adults and adolescents infected with human immunodeficiency virus. MMWR 1993; 42(no.RR-9):1–13Google Scholar
  39. 39.
    Pizzo PA, Eddy J, Faloon J. Acquired immune deficiency syndrome in children: current problems and therapeutic considerations. Am J Med 1988; 85:195–202PubMedGoogle Scholar
  40. 40.
    CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.MMWR;41(no.RR-17):19–92Google Scholar
  41. 41.
    CDC. Tuberculosis and human immunodeficiency virus: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR 1989;3:236–238, 243–250Google Scholar
  42. 42.
    CDC. Human immunodeficiency virus infection in transfusion recipients and their family members. MMWR 1987;36:137–140Google Scholar
  43. 43.
    McCray E, Onorato IM, et al. Sentinel surveillance of human immunodeficiency virus infection in sexually transmitted disease clinics in the United States. Sex Transm Dis 1992;19:235–241PubMedCrossRefGoogle Scholar
  44. 44.
    Centers for Disease Control and Prevention (CDC). National HIV Serosurveillance Summary—Results Through 1992. Publication HIV/NCID/11–93/ 036. Atlanta: US Department of Health and Human Services, Public Health Service, 1993Google Scholar
  45. 45.
    Guydish JR, Abramowitz A, Woods W, et al. Changes in needle sharing behavior among intravenous drug users: San Francisco, 1986–88. Am J Public Health 1990;2:253–271Google Scholar
  46. 46.
    Ward J. Kleinman SH, Douglas DK, Grindon AJ, Holmberg SD. Epidemiologic characteristics of blood donors with antibody to human immunodeficiency virus. Transfusion 1988;28:298–301PubMedCrossRefGoogle Scholar
  47. 47.
    Lindsay MK, Peterson HB, Feng TI, et al. Routine antepartum human immunodeficiency virus infection screening in an inner city population. Obstet Gynecol 1989;74:289–294PubMedGoogle Scholar
  48. 48.
    Sweeney PA, Onorato IM, Allen DM, et al. Sentinel surveillance of human immunodeficiency virus infection in women seeking reproductive health services in the United States, 1988–1990. Obstet Gynecol 1992;79:503–510PubMedGoogle Scholar
  49. 49.
    Gwinn M, Pappaioanou M, George R, et al. Prevalence of HIV infection in childbearing women in the United States: surveillance using newborn blood samples. JAMA 1991;265:1704–1708PubMedCrossRefGoogle Scholar
  50. 50.
    Davis S, Gwinn M, Wasser S. et al. HIV prevalence among US childbearing women, 1989–1992 [abstract 27]. In: Program and Abstracts of the First National Conference on Human Retroviruses and Related Infections, Washington, DC, December 12–16, 1993:60Google Scholar
  51. 51.
    Onorato IM, McCray E, Field Services Branch. Prevalence of human immunodeficiency virus infection among patients attending tuberculosis clinics in the United States. J Infect Dis 1992;165:87–92PubMedCrossRefGoogle Scholar
  52. 52.
    Raviglione MC, Narain JP, Kochi A. HIV-associated tuberculosis during the AIDS era. JAMA 1993;269:2865–2868CrossRefGoogle Scholar
  53. 53.
    Chaisson RE, Theuer CP, Schecter GF, Hopewell PC. HIV infection in patients with tuberculosis [abstract]. In: Abstracts, IV International Conference on AIDS, Stockholm, Book 2, 1988:313Google Scholar
  54. 54.
    Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545–550PubMedCrossRefGoogle Scholar
  55. 55.
    Selwyn PA, Sckell BM, Alcabes P, et al. High risk of active tuberculosis in HIV infected drug users with cutaneous anergy. JAMA 1992;268:504–509PubMedCrossRefGoogle Scholar
  56. 56.
    CDC. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR 1989;38:236–238, 243–250Google Scholar
  57. 57.
    CDC. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42(no.RR-7):1–8Google Scholar
  58. 58.
    Kelen GD, DiGiovanna T, Bisson L, et al. Human immunodeficiency virus infection in emergency department patients. JAMA 1989;262:516–522PubMedCrossRefGoogle Scholar
  59. 59.
    Soderstrom CA, Furth PA, Glasser D, et al. HIV infection rates in a trauma center treating predominantly rural blunt trauma victims. J Trauma 1989; 29:1526–1530PubMedCrossRefGoogle Scholar
  60. 60.
    Lewandowski C, Ognjan A, Rivers E, et al. HIV-1 and HTI,V-1 sere-prevalence in critically ill resuscitated emergency department patients. In: Abstracts for the V International Conference on AIDS. Montreal: Health and Welfare Canada, 1989:142Google Scholar
  61. 61.
    Gordin FM, Gibert C, Hawley HP, Willoughby A. Prevalence of human immunodeficiency virus and hepatitis B virus in unselected hospital admissions: implications for mandatory testing and universal precautions. J Infect Dis 1990;161:14–17PubMedCrossRefGoogle Scholar
  62. 62.
    Risi GF, Gaumer RH, Weeks S, Leeter JK, Sanders CV. Human immunodeficiency virus: risk of exposure among health care workers at a southern urban hospital. South Med J 1989;82:1079–1082PubMedCrossRefGoogle Scholar
  63. 63.
    St. Louis ME, Rauch KJ, Petersen LR, et al. Seroprevalence rates of human immunodeficiency virus infection at sentinel hospitals in the United States. N Engl J Med 1990;323:213–218CrossRefGoogle Scholar
  64. 64.
    Marcus R, Culver DH, Bell DM, et al. Risk of human immunodeficiency virus infection among emergency department workers. Am J Med 1993:94: 363–370PubMedCrossRefGoogle Scholar
  65. 65.
    Janssen RS, St. Louis ME, Satten GA, et al. HIV infection among patients in US acute-care hospitals: strategies for the counseling and testing of hospital patients. N Engl J Med 1992;327:445–452PubMedCrossRefGoogle Scholar
  66. 66.
    Recommendations for prevention of HIV transmission in health-care settings. MMWR 1987;36(suppl 2S):1S---18SGoogle Scholar
  67. 67.
    Tokars JI, Marcus R, Culver DH, et al. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993;118:913–919PubMedGoogle Scholar
  68. 68.
    Henderson DK, Fahey BJ, Willy M, et al. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-1) associated with clinical exposures: a prospective evaluation. Ann Intern MedGoogle Scholar
  69. 69.
    Tokars JI, Bell DM, Culver DH, et al. Percutaneous injuries during surgical procedures. JAMA 1992;267:2899–2904PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • John W. Ward

There are no affiliations available

Personalised recommendations